Keywords: کریزوتینیب; Lung cancer; NSCLC; Adenocarcinoma; Sarcomatoid; MET; Exon 14; Mutation; Crizotinib; Tyrosine kinase inhibitor; TKI; Non-small cell;
مقالات ISI کریزوتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کریزوتینیب; Lung cancer; ALK rearrangement; Crizotinib; Renal cystic lesion;
Keywords: کریزوتینیب; EML4-ALK rearrangement; Non-small cell lung cancer (NSCLC); Anaplastic lymphoma kinase inhibitors (ALK inhibitors); Crizotinib; Ceritinb; Alectinib;
Keywords: کریزوتینیب; Recombinant alcohol dehydrogenase; Recombinant glucose dehydrogenase; co-CLEAs; Crizotinib; (S)-1-(2,6-dichloro-3-fluorophenyl) phenethyl alcohol;
Keywords: کریزوتینیب; Crizotinib; Erlotinib; Phase I combination trial; MET inhibitor; EGFR inhibitor;
Keywords: کریزوتینیب; MET exon 14 skipping alterations; MET amplification; non-small cell lung cancer; crizotinib; MET inhibitor; MET overexpression;
Keywords: کریزوتینیب; Lung adenocarcinoma; Anaplastic lymphoma kinase; Crizotinib; Resistance; Small cell lung carcinoma;
Keywords: کریزوتینیب; Crizotinib; denosumab; fertility preservation; ovarian stimulation; targeted cancer treatment;
Keywords: کریزوتینیب; Anaplastic lymphoma kinase; Crizotinib; Cystic brain metastases; Non-small-cell lung cancer; Signet ring morphology;
Keywords: کریزوتینیب; Alectinib; Crizotinib; Drug induced interstitial lung disease; Molecular target drug;
Keywords: کریزوتینیب; Anaplastic lymphoma kinase; In situ hybridization; Immunohistochemistry; Crizotinib; Biopsy sample
Keywords: کریزوتینیب; Gravidez; Cancro do pulmão; Tratamento; EML4-AKL; CrizotinibPregnancy; Lung cancer; Treatment; EML4-AKL; Crizotinib
Keywords: کریزوتینیب; Pregnancy; Lung cancer; Treatment; EML4-AKL; Crizotinib; Gravidez; Cancro do pulmão; Tratamento; EML4-AKL; Crizotinib;
Keywords: کریزوتینیب; Anaplastic lymphoma kinase; Crizotinib; Creatinine; Glomerular filtration rate
Keywords: کریزوتینیب; Crizotinib; Renal insufficiency; Lung adenocarcinoma; Tyrosine kinase inhibitors; ALK; Toxicity
Keywords: کریزوتینیب; Renal cancer; Personalized therapy; Drug screen; MET; Crizotinib;
Keywords: کریزوتینیب; Crizotinib; Bovine serum albumin; Fluorescence spectroscopy; Molecular docking
Keywords: کریزوتینیب; ALK rearrangement; Brain metastases; Ceritinib; Crizotinib; NSCLC
Keywords: کریزوتینیب; Non-small cell lung cancer; Crizotinib; ALK rearrangement
Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
Keywords: کریزوتینیب; Inflammatory myofibroblastic tumor; Urinary bladder; ALK; Crizotinib;
Studies on the dynamic resolution of Crizotinib intermediate
Keywords: کریزوتینیب; Kinetic resolution; Lipases; Dynamic resolution; Crizotinib; Continuous-flow;
Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants
Keywords: کریزوتینیب; ALK translocation; Non-small cell lung cancer; Crizotinib; Next-generation sequencing; Variants;
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Keywords: کریزوتینیب; ALK-positive advanced non-small cell lung cancer; crizotinib; chemotherapy; phase III;
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Keywords: کریزوتینیب; ROS1; Crizotinib; Pemetrexed; Carcinoma; Non-small cell lung cancer;
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial
Keywords: کریزوتینیب; Alveolar rhabdomyosarcoma; ARMS; Metastasis; FOXO1; ALK; Crizotinib;
Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation
Keywords: کریزوتینیب; Crizotinib; DIC; Intensive care; NSCLC; ROS1;
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses
Keywords: کریزوتینیب; EGFR mutation; cMET amplification; Resistance; Crizotinib;
Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts
Keywords: کریزوتینیب; Crizo; crizotinib; Erlot; erlotinib; c-Met; Epidermal growth factor receptor; Erlotinib; Crizotinib; Glioblastoma; Primary xenograft;
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
Keywords: کریزوتینیب; Non-small cell lung cancer; PD-1 inhibitor; Nivolumab; Crizotinib; anaplastic lymphoma kinase translocation;
Simple and sensitive LC-MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study
Keywords: کریزوتینیب; Crizotinib; Oxidative metabolite; Pharmacokinetics; Human;
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib
Keywords: کریزوتینیب; MET amplification; Resistance; Osimertinib; Crizotinib;
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Keywords: کریزوتینیب; AFAT; afatinib; ALK; anaplastic lymphoma kinase; CRIZ; crizotinib; CS; calibration standard; CV; coefficient of variation; DMSO; dimethylsulfoxide; EGFR; epidermal growth factor receptor; ERLO; erlotinib; IQC; internal quality control; IS; internal standa
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer
Keywords: کریزوتینیب; ROS1 fusion partners; ROS1-rearranged lung cancer; Crizotinib; Efficacy; Nonâsmall cell lung cancer;
A major component of vitamin E, α-tocopherol inhibits the anti-tumor activity of crizotinib against cells transformed by EML4-ALK
Keywords: کریزوتینیب; EML4-ALK; Crizotinib; NSCLC; α-tocopherol; Vitamin E;
Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease
Keywords: کریزوتینیب; SH2 domain-containing inositol 5â²-phosphatase 2; Alzheimer's disease; Crizotinib; Tau;
Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
Keywords: کریزوتینیب; Crizotinib; Erlotinib; MET amplification; Non-small-cell lung cancer; Resistance;
Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma
Keywords: کریزوتینیب; TFG-ROS1; fusion gene; pediatric mesenchymal tumor; meningioma; crizotinib;
ReviewDrug resistance in ALK-positiveNon-small cell lungcancer patients
Keywords: کریزوتینیب; ALK; Point mutation; Crizotinib; Ceritinib; Alectinib; Lorlatinib;
Crizotinib chez les patients atteints de cancer bronchopulmonaire ROS1Â positifs
Keywords: کریزوتینیب; Cancer bronchique non à petites cellules; Crizotinib; Réarrangement de ROS1; Non-small cell lung cancer; Crizotinib; ROS1-positive;
ReviewOptimal management of ALK-positive NSCLC progressing on crizotinib
Keywords: کریزوتینیب; Alectinib; ALK-TKI; Brigatinib; Ceritinib; Crizotinib; Non-small cell lung cancer;
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations
Keywords: کریزوتینیب; MET amplification; Exon 14; Lung cancer; Crizotinib;
Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases
Keywords: کریزوتینیب; MET exon 14; NSCLC; Crizotinib; Cabozantinib; Brain metastases; Comprehensive genomic profiling;
Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study
Keywords: کریزوتینیب; Non-small cell lung cancer; Anaplastic lymphoma kinase inhibitor; Crizotinib; Alectinib; Sequential therapy; Overall survival;
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Keywords: کریزوتینیب; Advanced papillary renal cell carcinoma type 1 (PRCC1); MET mutations or amplification; MET tyrosine kinase inhibitor; Crizotinib;
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
Keywords: کریزوتینیب; MET Y1230C; Resistance mutation; Crizotinib; MET exon 14 skipping; Circulating tumor DNA;
ALK alterations and inhibition in lung cancer
Keywords: کریزوتینیب; Adenocarcinoma; Crizotinib; Oncogene addiction; Personalized medicine; Precision medicine; Targeted therapy;
F1174V mutation alters the ALK active conformation in response to Crizotinib in NSCLC: Insight from molecular simulations
Keywords: کریزوتینیب; NSCLC; ALK; Crizotinib; Molecular dynamic; F1174V mutation;
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: کریزوتینیب; Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
Recent Advances in Targeting ROS1 in Lung Cancer
Keywords: کریزوتینیب; ROS1 rearrangement; Non-small cell lung cancer; Crizotinib; ROS1 inhibitor; Resistance;
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: AÂ Retrospective Analysis
Keywords: کریزوتینیب; Alectinib; Combined PFS; Crizotinib;